Free Trial

Royalty Pharma (RPRX) Competitors

Royalty Pharma logo
$31.11 -0.68 (-2.14%)
Closing price 04:00 PM Eastern
Extended Trading
$30.39 -0.72 (-2.31%)
As of 04:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RPRX vs. CORT, JAZZ, PRGO, SUPN, PCRX, OMER, NKTR, ASMB, CPIX, and LLY

Should you be buying Royalty Pharma stock or one of its competitors? The main competitors of Royalty Pharma include Corcept Therapeutics (CORT), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Omeros (OMER), Nektar Therapeutics (NKTR), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), and Eli Lilly and Company (LLY). These companies are all part of the "pharmaceuticals" industry.

Royalty Pharma vs.

Royalty Pharma (NASDAQ:RPRX) and Corcept Therapeutics (NASDAQ:CORT) are both finance companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, community ranking, risk, analyst recommendations, valuation, earnings and institutional ownership.

In the previous week, Corcept Therapeutics had 43 more articles in the media than Royalty Pharma. MarketBeat recorded 60 mentions for Corcept Therapeutics and 17 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 1.25 beat Corcept Therapeutics' score of 0.51 indicating that Royalty Pharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Royalty Pharma
13 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Corcept Therapeutics
24 Very Positive mention(s)
5 Positive mention(s)
16 Neutral mention(s)
3 Negative mention(s)
2 Very Negative mention(s)
Positive

Royalty Pharma has a net margin of 37.94% compared to Corcept Therapeutics' net margin of 22.35%. Corcept Therapeutics' return on equity of 24.54% beat Royalty Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Royalty Pharma37.94% 24.40% 14.01%
Corcept Therapeutics 22.35%24.54%20.24%

Royalty Pharma presently has a consensus target price of $41.60, suggesting a potential upside of 34.82%. Corcept Therapeutics has a consensus target price of $143.25, suggesting a potential upside of 89.15%. Given Corcept Therapeutics' higher probable upside, analysts plainly believe Corcept Therapeutics is more favorable than Royalty Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Royalty Pharma
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.00
Corcept Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

Royalty Pharma has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 0.14, suggesting that its share price is 86% less volatile than the S&P 500.

54.3% of Royalty Pharma shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 18.9% of Royalty Pharma shares are owned by company insiders. Comparatively, 20.5% of Corcept Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Corcept Therapeutics received 221 more outperform votes than Royalty Pharma when rated by MarketBeat users. Likewise, 71.37% of users gave Corcept Therapeutics an outperform vote while only 67.99% of users gave Royalty Pharma an outperform vote.

CompanyUnderperformOutperform
Royalty PharmaOutperform Votes
325
67.99%
Underperform Votes
153
32.01%
Corcept TherapeuticsOutperform Votes
546
71.37%
Underperform Votes
219
28.63%

Royalty Pharma has higher revenue and earnings than Corcept Therapeutics. Royalty Pharma is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Royalty Pharma$2.26B7.86$858.98M$1.4521.28
Corcept Therapeutics$675.04M11.84$106.14M$1.2461.08

Summary

Corcept Therapeutics beats Royalty Pharma on 11 of the 18 factors compared between the two stocks.

Remove Ads
Get Royalty Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for RPRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RPRX vs. The Competition

MetricRoyalty PharmaPharmaceutical IndustryFinance SectorNASDAQ Exchange
Market Cap$17.76B$6.51B$10.53B$7.14B
Dividend Yield2.82%2.85%5.42%4.05%
P/E Ratio21.256.7721.3517.35
Price / Sales7.86188.6224.9684.30
Price / Cash7.9465.6717.6234.64
Price / Book1.725.632.583.78
Net Income$858.98M$142.37M$1.03B$247.18M
7 Day Performance-1.64%-11.25%-5.06%-7.74%
1 Month Performance-7.40%-14.25%494.21%-10.35%
1 Year Performance7.43%-18.14%530.63%-7.76%

Royalty Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RPRX
Royalty Pharma
4.6744 of 5 stars
$31.11
-2.1%
$41.60
+33.7%
+10.4%$17.93B$2.26B21.4680Positive News
High Trading Volume
CORT
Corcept Therapeutics
4.3127 of 5 stars
$114.22
+109.1%
$127.00
+11.2%
+209.4%$12.05B$675.04M90.65300Analyst Forecast
Insider Trade
Options Volume
Analyst Revision
Gap Down
High Trading Volume
JAZZ
Jazz Pharmaceuticals
4.8567 of 5 stars
$124.15
+1.0%
$187.71
+51.2%
+3.3%$7.54B$4.07B17.493,200Insider Trade
Positive News
Gap Down
High Trading Volume
PRGO
Perrigo
4.9213 of 5 stars
$28.07
+0.0%
$33.00
+17.6%
-13.3%$3.83B$4.37B-23.998,900Short Interest ↓
News Coverage
Positive News
Gap Down
SUPN
Supernus Pharmaceuticals
2.7786 of 5 stars
$32.75
+1.4%
$36.00
+9.9%
-4.0%$1.83B$661.82M30.61580Analyst Upgrade
Short Interest ↓
PCRX
Pacira BioSciences
3.2985 of 5 stars
$24.85
-0.2%
$27.22
+9.5%
-16.3%$1.15B$700.97M-12.24720Gap Down
OMER
Omeros
3.4347 of 5 stars
$8.22
-3.0%
$22.50
+173.7%
+133.7%$476.35MN/A-3.56210Analyst Forecast
Analyst Revision
News Coverage
NKTR
Nektar Therapeutics
4.2356 of 5 stars
$0.68
-7.9%
$4.92
+623.0%
-42.3%$126.55M$98.43M-0.81220Analyst Revision
Gap Down
ASMB
Assembly Biosciences
3.3849 of 5 stars
$9.56
-10.0%
$33.00
+245.2%
-32.5%$71.73M$28.52M-1.42100Gap Down
CPIX
Cumberland Pharmaceuticals
1.0015 of 5 stars
$4.23
-4.1%
N/A+150.0%$59.09M$37.87M-5.4980
LLY
Eli Lilly and Company
4.9037 of 5 stars
$825.42
+0.4%
$1,009.72
+22.3%
+1.6%$782.64B$45.04B70.4939,000Gap Down
Remove Ads

Related Companies and Tools


This page (NASDAQ:RPRX) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners